ATTENTION ESSA Pharma Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights ...

As the U.S. stock market reaches record highs amid an election-fueled rally, investors are increasingly exploring diverse opportunities to capitalize on this momentum. Penny stocks, often seen as a ...

Essa Pharma’s sole clinical-stage candidate was on track to fall short against Xtandi in a phase 2 prostate cancer trial, ...

ESSA Pharma (NASDAQ:EPIX) plummeted about 70% premarket on Friday after ending its Phase 2 trial for a prostate cancer ...

NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are ...

ESSA Pharma (NASDAQ:EPIX), a biotechnology company focused on developing treatments for metastatic castration-resistant ...

ESSA Pharma terminates its Phase 2 masofaniten trial in prostate cancer after interim data shows no added efficacy over ...

In a report released on November 1, Maury Raycroft from Jefferies downgraded ESSA Pharma (EPIX – Research Report) to a Hold, with a price ...

Essa Pharma's stock price plunged after the clinical-stage pharmaceutical company said it was throwing in the towel on its lead product candidate and exploring strategic alternatives. Shares of the ...

US clinical-stage firm ESSA Pharma has made the decision to terminate the Phase II clinical trial evaluating in a 2:1 ...

Piper Sandler analyst Joseph Catanzaro downgraded the rating on ESSA Pharma (EPIX – Research Report) to a Hold today, setting a price ...